Docoh
Loading...

SNGX Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Company profile

Ticker
SNGX, SNGXW
Exchange
CEO
Christopher Schaber
Employees
Incorporated
Location
Fiscal year end
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
IRS number
411505029

SNGX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Mar 21
11 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Soligenix earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 18.68M 18.68M 18.68M 18.68M 18.68M 18.68M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.83M 1.55M 1.37M 954.54K
Cash used (since last report) n/a n/a 6.17M 5.22M 4.64M 3.22M
Cash remaining n/a n/a 12.51M 13.45M 14.04M 15.46M
Runway (months of cash) n/a n/a 6.8 8.7 10.2 16.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 Jan 21 Christopher J Schaber Option Common Stock Grant Aquire A No No 1.28 60,000 76.8K 60,000
10 Dec 20 Oreola Donini Option Common Stock Grant Aquire A No No 2.34 70,000 163.8K 70,000
10 Dec 20 Christopher J Schaber Option Common Stock Grant Aquire A No No 2.34 60,000 140.4K 60,000
10 Dec 20 Richard Straube Option Common Stock Grant Aquire A No No 2.34 40,000 93.6K 40,000
10 Dec 20 Jonathan L. Guarino Stock Option COMMON STOCK Grant Aquire A No No 2.34 40,000 93.6K 40,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 35 29 +20.7%
Opened positions 11 2 +450.0%
Closed positions 5 6 -16.7%
Increased positions 6 14 -57.1%
Reduced positions 4 4
13F shares
Current Prev Q Change
Total value 3.84M 4.99M -23.1%
Total shares 3M 2.8M +7.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 909.16K $1.16M +4.4%
Knoll Capital Management 787.83K $1.01M 0.0%
First Wilshire Securities Management 350K $448K +40.0%
Geode Capital Management 128.4K $164K 0.0%
California Public Employees Retirement System 126.17K $161K NEW
Gsa Capital Partners 118.69K $152K -12.6%
BLK Blackrock 95.52K $122K +22.8%
Plante Moran Financial Advisors 71.66K $92K 0.0%
NTRS Northern Trust 48.47K $62K 0.0%
VIRT Virtu Financial 44.1K $56K -1.7%
Largest transactions
Shares Bought/sold Change
California Public Employees Retirement System 126.17K +126.17K NEW
First Wilshire Securities Management 350K +100K +40.0%
FNY Investment Advisers 0 -89.5K EXIT
Squarepoint Ops 0 -71.83K EXIT
ARGI Investment Services 40.88K +40.88K NEW
Occudo Quantitative Strategies 39.19K +39.19K NEW
Vanguard 909.16K +37.97K +4.4%
Two Sigma Securities 30.9K +30.9K NEW
BK Bank Of New York Mellon 28.47K +28.47K NEW
Wedbush Securities 0 -25.2K EXIT

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accommodate, accrual, add, admitted, advisory, affirmative, aim, alia, allege, alleged, annum, answered, apparent, apprising, arbitration, attestation, automation, Baltimore, Bank, BDS, biased, biorxiv, borrow, borrowed, borrowing, Boston, BSX, BTG, Burkholderia, carryover, case, cellular, Chase, choose, CiVaxTM, cleaning, companion, compendia, County, CoVaccine, Daavlin, dataset, deeper, deeply, default, deviation, distancing, downstream, drawn, EBS, EMOB, emulsified, energy, enriched, EPDG, EVD, exhausted, faulty, flow, flu, forgiven, fresh, Gaithersburg, GP, grow, House, HT, humoral, HyBiopharma, Hypericum, impede, imperative, incentivize, inter, intercepted, invoice, invoiced, IRS, Japanese, JPMorgan, judgement, Kura, lender, lien, loan, mandated, manipulation, manuscript, mask, mediated, Medison, Mercer, merchantability, methodology, monthly, moving, mucobuccal, NB, necessitate, notification, pandemic, paper, patch, Paycheck, payroll, penetrating, penetration, plaque, pledged, Pontifax, potency, PPP, prepayment, preprint, prototype, quickly, reading, remotely, renegotiate, repay, repayment, repurchasing, restructuring, revealed, sanitation, Simphotek, Singapore, social, SOM, sought, Spike, stored, strong, subset, substitute, subtopic, Sudan, talent, top, tranche, trend, turnover, uneven, unjustly, unpaid, unsecured, upstream, usage, venture, vi, vigorously, vii, viii, warranty, workplace, Zaire
Removed: Amir, assigned, attainment, attribute, Ave, Brownlie, Carol, clarification, collection, dispositive, Ecker, Extensivein, FluorescentLightActivatedSyntheticHypericin, fourth, Frankenfield, guidance, inInternal, Intrexon, joined, Karen, Krumeich, Lancaster, legally, lesser, Lincoln, Managing, Master, modulatingINNATE, offered, ofHypericum, OrbeShield, owner, PA, Park, participated, predominantly, reserved, RiVax®and, RiVax®bulk, RiVax®testing, RiVax®under, ThermoVax®development, Wayne, Zolina®and